Multifaceted roles for BCL3 in cancer: a proto-oncogene comes of age.
BCL3
C-Myc
Hallmarks
NF-kappaB
SMAD3
STAT3
Targeted therapy
Transcription
WNT
Journal
Molecular cancer
ISSN: 1476-4598
Titre abrégé: Mol Cancer
Pays: England
ID NLM: 101147698
Informations de publication
Date de publication:
09 Jan 2024
09 Jan 2024
Historique:
received:
27
10
2023
accepted:
20
12
2023
medline:
10
1
2024
pubmed:
10
1
2024
entrez:
9
1
2024
Statut:
epublish
Résumé
In the early 1990's a group of unrelated genes were identified from the sites of recurring translocations in B-cell lymphomas. Despite sharing the nomenclature 'Bcl', and an association with blood-borne cancer, these genes have unrelated functions. Of these genes, BCL2 is best known as a key cancer target involved in the regulation of caspases and other cell viability mechanisms. BCL3 on the other hand was originally identified as a non-canonical regulator of NF-kB transcription factor pathways - a signaling mechanism associated with important cell outcomes including many of the hallmarks of cancer. Most of the early investigations into BCL3 function have since focused on its role in NF-kB mediated cell proliferation, inflammation/immunity and cancer. However, recent evidence is coming to light that this protein directly interacts with and modulates a number of other signaling pathways including DNA damage repair, WNT/β-catenin, AKT, TGFβ/SMAD3 and STAT3 - all of which have key roles in cancer development, metastatic progression and treatment of solid tumours. Here we review the direct evidence demonstrating BCL3's central role in a transcriptional network of signaling pathways that modulate cancer biology and treatment response in a range of solid tumour types and propose common mechanisms of action of BCL3 which may be exploited in the future to target its oncogenic effects for patient benefit.
Identifiants
pubmed: 38195591
doi: 10.1186/s12943-023-01922-8
pii: 10.1186/s12943-023-01922-8
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
7Informations de copyright
© 2024. The Author(s).
Références
McKeithan TW, Takimoto GS, Ohno H, Bjorling VS, Morgan R, Hecht BK, et al. BCL3 rearrangements and t(14;19) in chronic lymphocytic leukemia and other B-cell malignancies: a molecular and cytogenetic study. Genes Chromosomes Cancer. 1997;20:64–72.
pubmed: 9290956
doi: 10.1002/(SICI)1098-2264(199709)20:1<64::AID-GCC10>3.0.CO;2-F
Michaux L, Dierlamm J, Wlodarska I, Bours V, Van den Berghe H, Hagemeijer A. T(14;19)/BCL3 rearrangements in lymphoproliferative disorders: a review of 23 cases. Cancer Genet Cytogenet. 1997;94:36–43.
pubmed: 9078289
doi: 10.1016/S0165-4608(96)00247-6
Ohno H, Takimoto G, McKeithan TW. The candidate proto-oncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control. Cell. 1990;60:991–7.
pubmed: 2180580
doi: 10.1016/0092-8674(90)90347-H
Gauwerky CE, Huebner K, Isobe M, Nowell PC, Croce CM. Activation of MYC in a masked t(8;17) translocation results in an aggressive B-cell leukemia. Proc Natl Acad Sci U S A. 1989;86:8867–71.
pubmed: 2682663
pmcid: 298391
doi: 10.1073/pnas.86.22.8867
Yano T, Sander CA, Andrade RE, Gauwerky CE, Croce CM, Longo DL, et al. Molecular analysis of the BCL-3 locus at chromosome 17q22 in B-cell neoplasms. Blood. 1993;82:1813–9.
pubmed: 8400234
doi: 10.1182/blood.V82.6.1813.1813
Franzoso G, Bours V, Park S, Tomita-Yamaguchi M, Kelly K, Siebenlist U. The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-kappa B-mediated inhibition. Nature. 1992;359:339–42.
pubmed: 1406939
doi: 10.1038/359339a0
Wulczyn FG, Naumann M, Scheidereit C. Candidate proto-oncogene bcl-3 encodes a subunit-specific inhibitor of transcription factor NF-kappa B. Nature. 1992;358:597–9.
pubmed: 1501714
doi: 10.1038/358597a0
Kerr LD, Duckett CS, Wamsley P, Zhang Q, Chiao P, Nabel G, et al. The proto-oncogene bcl-3 encodes an I kappa B protein. Genes Dev. 1992;6:2352–63.
pubmed: 1459457
doi: 10.1101/gad.6.12a.2352
Nolan GP, Fujita T, Bhatia K, Huppi C, Liou HC, Scott ML, et al. The bcl-3 proto-oncogene encodes a nuclear I kappa B-like molecule that preferentially interacts with NF-kappa B p50 and p52 in a phosphorylation-dependent manner. Mol Cell Biol. 1993;13:3557–66.
pubmed: 8497270
pmcid: 359825
Michel F, Soler-Lopez M, Petosa C, Cramer P, Siebenlist U, Müller CW. Crystal structure of the ankyrin repeat domain of Bcl-3: a unique member of the IkappaB protein family. EMBO J. 2001;20:6180–90.
pubmed: 11707390
pmcid: 125740
doi: 10.1093/emboj/20.22.6180
Liu Z, Jiang Y, Hou Y, Hu Y, Cao X, Tao Y, et al. The IκB family member Bcl-3 stabilizes c-Myc in colorectal cancer. J Mol Cell Biol. 2013;5:280–2.
pubmed: 23794716
doi: 10.1093/jmcb/mjt020
Urban BC, Collard TJ, Eagle CJ, Southern SL, Greenhough A, Hamdollah-Zadeh M, et al. BCL-3 expression promotes colorectal tumorigenesis through activation of AKT signaling. Gut. 2016;65:1151–64.
pubmed: 26033966
doi: 10.1136/gutjnl-2014-308270
Legge DN, Shephard AP, Collard TJ, Greenhough A, Chambers AC, Clarkson RW, et al. BCL-3 promotes a cancer stem cell phenotype by enhancing β-catenin signaling in colorectal tumour cells. Dis Model Mech. 2019;12
Chen X, Cao X, Sun X, Lei R, Chen P, Zhao Y, et al. Bcl-3 regulates TGFβ signaling by stabilizing Smad3 during breast cancer pulmonary metastasis. Cell Death Dis. 2016;7:e2508.
pubmed: 27906182
pmcid: 5261001
doi: 10.1038/cddis.2016.405
Wu J, Li L, Jiang G, Zhan H, Wang N. B-cell CLL/lymphoma 3 promotes glioma cell proliferation and inhibits apoptosis through the oncogenic STAT3 pathway. Int J Oncol. 2016;49:2471–9.
pubmed: 27748795
doi: 10.3892/ijo.2016.3729
Legge DN, Chambers AC, Parker CT, Timms P, Collard TJ, Williams AC. The role of B-cell Lymphoma-3 (BCL-3) in enabling the hallmarks of cancer: implications for the treatment of colorectal carcinogenesis. Carcinogenesis. 2020;41:249–56.
pubmed: 31930327
pmcid: 7221501
doi: 10.1093/carcin/bgaa003
Maldonado V, Melendez-Zajgla J. Role of Bcl-3 in solid tumors. Mol Cancer. 2011;10:152.
pubmed: 22195643
pmcid: 3258214
doi: 10.1186/1476-4598-10-152
Liu H, Zeng L, Yang Y, Guo C, Wang H. Bcl-3: a double-edged sword in immune cells and inflammation. Front Immunol. 2022;13:847699.
pubmed: 35355979
pmcid: 8959985
doi: 10.3389/fimmu.2022.847699
Mirzaei S, Saghari S, Bassiri F, Raesi R, Zarrabi A, Hushmandi K, et al. NF-κB as a regulator of cancer metastasis and therapy response: a focus on epithelial-mesenchymal transition. J Cell Physiol. 2022;237:2770–95.
pubmed: 35561232
doi: 10.1002/jcp.30759
Inoue J, Gohda J, Akiyama T, Semba K. NF-kappaB activation in development and progression of cancer. Cancer Sci. 2007;98:268–74.
pubmed: 17270016
doi: 10.1111/j.1349-7006.2007.00389.x
Zhang Q, Lenardo MJ, Baltimore D. 30 years of NF-κB: a blossoming of relevance to human pathobiology. Cell. 2017;168:37–57.
pubmed: 28086098
pmcid: 5268070
doi: 10.1016/j.cell.2016.12.012
Dechend R, Hirano F, Lehmann K, Heissmeyer V, Ansieau S, Wulczyn FG, et al. The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators. Oncogene. 1999;18:3316–23.
pubmed: 10362352
doi: 10.1038/sj.onc.1202717
Bours V, Franzoso G, Azarenko V, Park S, Kanno T, Brown K, et al. The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers. Cell. 1993;72:729–39.
pubmed: 8453667
doi: 10.1016/0092-8674(93)90401-B
Fujita T, Nolan GP, Liou HC, Scott ML, Baltimore D. The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-kappa B p50 homodimers. Genes Dev. 1993;7:1354–63.
pubmed: 8330739
doi: 10.1101/gad.7.7b.1354
Inoue J, Takahara T, Akizawa T, Hino O. Bcl-3, a member of the I kappa B proteins, has distinct specificity towards the Rel family of proteins. Oncogene. 1993;8:2067–73.
pubmed: 8336935
Franzoso G, Bours V, Azarenko V, Park S, Tomita-Yamaguchi M, Kanno T, et al. The oncoprotein Bcl-3 can facilitate NF-kappa B-mediated transactivation by removing inhibiting p50 homodimers from select kappa B sites. EMBO J. 1993;12:3893–901.
pubmed: 8404857
pmcid: 413672
doi: 10.1002/j.1460-2075.1993.tb06067.x
Miyazaki I, Simizu S, Okumura H, Takagi S, Osada H. A small-molecule inhibitor shows that pirin regulates migration of melanoma cells. Nat Chem Biol. 2010;6:667–73.
pubmed: 20711196
doi: 10.1038/nchembio.423
Zhang Q, Didonato JA, Karin M, McKeithan TW. BCL3 encodes a nuclear protein which can alter the subcellular location of NF-kappa B proteins. Mol Cell Biol. 1994;14:3915–26.
pubmed: 8196632
pmcid: 358758
Viatour P, Dejardin E, Warnier M, Lair F, Claudio E, Bureau F, et al. GSK3-mediated BCL-3 phosphorylation modulates its degradation and its oncogenicity. Mol Cell. 2004;16:35–45.
pubmed: 15469820
doi: 10.1016/j.molcel.2004.09.004
Carmody RJ, Ruan Q, Palmer S, Hilliard B, Chen YH. Negative regulation of toll-like receptor signaling by NF-kappaB p50 ubiquitination blockade. Science. 2007;317:675–8.
pubmed: 17673665
doi: 10.1126/science.1142953
Viatour P, Merville MP, Bours V, Chariot A. Protein phosphorylation as a key mechanism for the regulation of BCL-3 activity. Cell Cycle. 2004;3:1498–501.
pubmed: 15611665
doi: 10.4161/cc.3.12.1328
Wang VY, Huang W, Asagiri M, Spann N, Hoffmann A, Glass C, et al. The transcriptional specificity of NF-κB dimers is coded within the κB DNA response elements. Cell Rep. 2012;2:824–39.
pubmed: 23063365
pmcid: 4167904
doi: 10.1016/j.celrep.2012.08.042
Keutgens A, Zhang X, Shostak K, Robert I, Olivier S, Vanderplasschen A, et al. BCL-3 degradation involves its polyubiquitination through a FBW7-independent pathway and its binding to the proteasome subunit PSMB1. J Biol Chem. 2010;285:25831–40.
pubmed: 20558726
pmcid: 2919145
doi: 10.1074/jbc.M110.112128
Schwarz EM, Krimpenfort P, Berns A, Verma IM. Immunological defects in mice with a targeted disruption in Bcl-3. Genes Dev. 1997;11:187–97.
pubmed: 9009202
doi: 10.1101/gad.11.2.187
Franzoso G, Carlson L, Scharton-Kersten T, Shores EW, Epstein S, Grinberg A, et al. Critical roles for the Bcl-3 oncoprotein in T cell-mediated immunity, splenic microarchitecture, and germinal center reactions. Immunity. 1997;6:479–90.
pubmed: 9133427
doi: 10.1016/S1074-7613(00)80291-5
Gerondakis S, Grossmann M, Nakamura Y, Pohl T, Grumont R. Genetic approaches in mice to understand Rel/NF-kappaB and IkappaB function: transgenics and knockouts. Oncogene. 1999;18:6888–95.
pubmed: 10602464
doi: 10.1038/sj.onc.1203236
Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol. 2006;16:253–64.
doi: 10.1016/j.semcancer.2006.07.014
Dang CV. C-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol. 1999;19:1–11.
pubmed: 9858526
pmcid: 83860
doi: 10.1128/MCB.19.1.1
Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, et al. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J. 2004;23:2116–25.
pubmed: 15103331
pmcid: 424394
doi: 10.1038/sj.emboj.7600217
Huo J, Chen X, Zhang H, Hu Y, Jiang Y, Liu S, et al. Bcl-3 promotes proliferation and chemosensitivity in BL1 subtype of TNBC cells. Acta Biochim Biophys Sin Shanghai. 2018;50:1141–9.
pubmed: 30289427
doi: 10.1093/abbs/gmy117
Hashimoto S, Hashimoto A, Muromoto R, Kitai Y, Oritani K, Matsuda T. Central roles of STAT3-mediated signals in onset and development of cancers: tumorigenesis and Immunosurveillance. Cells. 2022;11
Brocke-Heidrich K, Ge B, Cvijic H, Pfeifer G, Löffler D, Henze C, et al. BCL3 is induced by IL-6 via Stat3 binding to intronic enhancer HS4 and represses its own transcription. Oncogene. 2006;25:7297–304.
pubmed: 16732314
doi: 10.1038/sj.onc.1209711
Maldonado V, Espinosa M, Pruefer F, Patiño N, Ceballos-Canciono G, Urzua U, et al. Gene regulation by BCL3 in a cervical cancer cell line. Folia Biol (Praha). 2010;56:183–93.
pubmed: 20974051
Wakefield A, Soukupova J, Montagne A, Ranger J, French R, Muller WJ, et al. Bcl3 selectively promotes metastasis of ERBB2-driven mammary tumors. Cancer Res. 2013;73:745–55.
pubmed: 23149915
doi: 10.1158/0008-5472.CAN-12-1321
Zhao H, Wang W, Zhao Q, Hu G, Deng K, Liu Y. BCL3 exerts an oncogenic function by regulating STAT3 in human cervical cancer. Onco Targets Ther. 2016;9:6619–29.
pubmed: 27822067
pmcid: 5087794
doi: 10.2147/OTT.S118184
Yun S, Yun CW, Lee JH, Kim S, Lee SH. Cripto enhances proliferation and survival of mesenchymal stem cells by up-regulating JAK2/STAT3 pathway in a GRP78-dependent manner. Biomol Ther (Seoul). 2018;26:464–73.
pubmed: 28835002
doi: 10.4062/biomolther.2017.099
Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signaling. Nature. 2003;425:577–84.
pubmed: 14534577
doi: 10.1038/nature02006
Li K, Cui M, Zhang K, Wang G, Zhai S. LncRNA CRNDE affects the proliferation and apoptosis of vascular smooth muscle cells in abdominal aortic aneurysms by regulating the expression of Smad3 by Bcl-3. Cell Cycle. 2020;19:1036–47.
pubmed: 32240036
pmcid: 7217363
doi: 10.1080/15384101.2020.1743915
Zhao K, Cui X, Wang Q, Fang C, Tan Y, Wang Y, et al. RUNX1 contributes to the mesenchymal subtype of glioblastoma in a TGFβ pathway-dependent manner. Cell Death Dis. 2019;10:877.
pubmed: 31754093
pmcid: 6872557
doi: 10.1038/s41419-019-2108-x
Noorolyai S, Shajari N, Baghbani E, Sadreddini S, Baradaran B. The relation between PI3K/AKT signaling pathway and cancer. Gene. 2019;698:120–8.
pubmed: 30849534
doi: 10.1016/j.gene.2019.02.076
Li W, Yang W, Yang C. Knockdown of Bcl-3 alleviates psoriasis and dyslipidemia comorbidity by regulating Akt pathway. Allergol Immunopathol (Madr). 2022;50:115–21.
pubmed: 36335454
doi: 10.15586/aei.v50i6.683
Wang VY, Li Y, Kim D, Zhong X, Du Q, Ghassemian M, et al. Bcl3 phosphorylation by Akt, Erk2, and IKK is required for its transcriptional activity. Mol Cell. 2017;67:484–497.e485.
pubmed: 28689659
pmcid: 6571149
doi: 10.1016/j.molcel.2017.06.011
Anastas JN, Moon RT. WNT signaling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13:11–26.
pubmed: 23258168
doi: 10.1038/nrc3419
Reya T, Clevers H. Wnt signaling in stem cells and cancer. Nature. 2005;434:843–50.
pubmed: 15829953
doi: 10.1038/nature03319
Chen CY, Lee DS, Yan YT, Shen CN, Hwang SM, Lee ST, et al. Bcl3 bridges LIF-STAT3 to Oct4 signaling in the maintenance of Naïve pluripotency. Stem Cells. 2015;33:3468–80.
pubmed: 26303070
doi: 10.1002/stem.2201
Chen X, Wang C, Jiang Y, Wang Q, Tao Y, Zhang H, et al. Bcl-3 promotes Wnt signaling by maintaining the acetylation of β-catenin at lysine 49 in colorectal cancer. Signal Transduct Target Ther. 2020;5:52.
pubmed: 32355204
pmcid: 7193563
doi: 10.1038/s41392-020-0138-6
Valenta T, Lukas J, Korinek V. HMG box transcription factor TCF-4's interaction with CtBP1 controls the expression of the Wnt target Axin2/Conductin in human embryonic kidney cells. Nucleic Acids Res. 2003;31:2369–80.
pubmed: 12711682
pmcid: 154232
doi: 10.1093/nar/gkg346
Choi HJ, Lee JM, Kim H, Nam HJ, Shin HJ, Kim D, et al. Bcl3-dependent stabilization of CtBP1 is crucial for the inhibition of apoptosis and tumor progression in breast cancer. Biochem Biophys Res Commun. 2010;400:396–402.
pubmed: 20800578
doi: 10.1016/j.bbrc.2010.08.084
Collard TJ, Fallatah HM, Greenhough A, Paraskeva C, Williams AC. BCL-3 promotes cyclooxygenase-2/prostaglandin E2 signaling in colorectal cancer. Int J Oncol. 2020;56:1304–13.
pubmed: 32319612
Tong D, Liu Q, Wang LA, Xie Q, Pang J, Huang Y, et al. The roles of the COX2/PGE2/EP axis in therapeutic resistance. Cancer Metastasis Rev. 2018;37:355–68.
pubmed: 30094570
doi: 10.1007/s10555-018-9752-y
McKeithan TW, Ohno H, Diaz MO. Identification of a transcriptional unit adjacent to the breakpoint in the 14;19 translocation of chronic lymphocytic leukemia. Genes Chromosomes Cancer. 1990;1:247–55.
pubmed: 2083219
doi: 10.1002/gcc.2870010310
Canoz O, Rassidakis GZ, Admirand JH, Medeiros LJ. Immunohistochemical detection of BCL-3 in lymphoid neoplasms: a survey of 353 cases. Mod Pathol. 2004;17:911–7.
pubmed: 15105810
doi: 10.1038/modpathol.3800140
Rossi D, Deambrogi C, Monti S, Cresta S, De Paoli L, Fangazio M, et al. BCL3 translocation in CLL with typical phenotype: assessment of frequency, association with cytogenetic subgroups, and prognostic significance. Br J Haematol. 2010;150:702–4.
pubmed: 20553272
doi: 10.1111/j.1365-2141.2010.08255.x
Soma LA, Gollin SM, Remstein ED, Ketterling RP, Flynn HC, Rajasenan KK, et al. Splenic small B-cell lymphoma with IGH/BCL3 translocation. Hum Pathol. 2006;37:218–30.
pubmed: 16426923
doi: 10.1016/j.humpath.2005.09.025
Ohno H, Nishikori M, Maesako Y, Haga H. Reappraisal of BCL3 as a molecular marker of anaplastic large cell lymphoma. Int J Hematol. 2005;82:397–405.
pubmed: 16533741
doi: 10.1532/IJH97.05045
Martin-Subero JI, Wlodarska I, Bastard C, Picquenot JM, Höppner J, Giefing M, et al. Chromosomal rearrangements involving the BCL3 locus are recurrent in classical Hodgkin and peripheral T-cell lymphoma. Blood. 2006;108:401–2. author reply 402-403
pubmed: 16790585
doi: 10.1182/blood-2005-09-3843
Carbo-Meix A, Guijarro F, Wang L, Grau M, Royo R, Frigola G, et al. BCL3-rearrangements in B-cell lymphoid neoplasms occur in two breakpoint clusters associated with different diseases. Haematologica. 2023; https://doi.org/10.3324/haematol.2023.283209 .
Mathas S, Jöhrens K, Joos S, Lietz A, Hummel F, Janz M, et al. Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas. Blood. 2005;106:4287–93.
pubmed: 16123212
doi: 10.1182/blood-2004-09-3620
Andrews N, Helliwell T, Walker C, Jones AS. Differing expression of bax and bcl-3 may influence the different cure rates in mouth and orophayrngeal cancer. Clin Otolaryngol Allied Sci. 2000;25:570–6.
pubmed: 11122304
doi: 10.1046/j.1365-2273.2000.00422-12.x
Thornburg NJ, Pathmanathan R, Raab-Traub N. Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. Cancer Res. 2003;63:8293–301.
pubmed: 14678988
Mishra A, Bharti AC, Varghese P, Saluja D, Das BC. Differential expression and activation of NF-kappaB family proteins during oral carcinogenesis: role of high risk human papillomavirus infection. Int J Cancer. 2006;119:2840–50.
pubmed: 16998793
doi: 10.1002/ijc.22262
Chung GT, Lou WP, Chow C, To KF, Choy KW, Leung AW, et al. Constitutive activation of distinct NF-κB signals in EBV-associated nasopharyngeal carcinoma. J Pathol. 2013;231:311–22.
pubmed: 23868181
doi: 10.1002/path.4239
Rassidakis GZ, Oyarzo MP, Medeiros LJ. BCL-3 overexpression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Blood. 2003;102:1146–7.
pubmed: 12869493
doi: 10.1182/blood-2003-04-1366
Niu Y, Yang X, Chen Y, Zhang L, Jin X, Tang Y, et al. BCL3 expression is a potential prognostic and predictive biomarker in acute myeloid leukemia of FAB subtype M2. Pathol Oncol Res. 2019;25:541–8.
pubmed: 30357752
doi: 10.1007/s12253-018-0476-7
Brenne AT, Fagerli UM, Shaughnessy JD Jr, Våtsveen TK, Rø TB, Hella H, et al. High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis. Eur J Haematol. 2009;82:354–63.
pubmed: 19191868
pmcid: 2704939
doi: 10.1111/j.1600-0609.2009.01225.x
Pratt MA, Bishop TE, White D, Yasvinski G, Ménard M, Niu MY, et al. Estrogen withdrawal-induced NF-kappaB activity and bcl-3 expression in breast cancer cells: roles in growth and hormone independence. Mol Cell Biol. 2003;23:6887–900.
pubmed: 12972607
pmcid: 193930
doi: 10.1128/MCB.23.19.6887-6900.2003
Schulten HJ, Bangash M, Karim S, Dallol A, Hussein D, Merdad A, et al. Comprehensive molecular biomarker identification in breast cancer brain metastases. J Transl Med. 2017;15:269.
pubmed: 29287594
pmcid: 5747948
doi: 10.1186/s12967-017-1370-x
Czapiewski P, Cornelius M, Hartig R, Kalinski T, Haybaeck J, Dittmer A, et al. BCL3 expression is strongly associated with the occurrence of breast cancer relapse under tamoxifen treatment in a retrospective cohort study. Virchows Arch. 2022;480:529–41.
pubmed: 35020071
pmcid: 8989858
doi: 10.1007/s00428-021-03238-8
Pallares J, Martínez-Guitarte JL, Dolcet X, Llobet D, Rue M, Palacios J, et al. Abnormalities in the NF-kappaB family and related proteins in endometrial carcinoma. J Pathol. 2004;204:569–77.
pubmed: 15481028
doi: 10.1002/path.1666
O'Neil BH, Bůzková P, Farrah H, Kashatus D, Sanoff H, Goldberg RM, et al. Expression of nuclear factor-kappaB family proteins in hepatocellular carcinomas. Oncology. 2007;72:97–104.
pubmed: 18025803
doi: 10.1159/000111116
Tu K, Liu Z, Yao B, Xue Y, Xu M, Dou C, et al. BCL-3 promotes the tumor growth of hepatocellular carcinoma by regulating cell proliferation and the cell cycle through cyclin D1. Oncol Rep. 2016;35:2382–90.
pubmed: 26882953
doi: 10.3892/or.2016.4616
Uffort DG, Grimm EA, Ellerhorst JA. NF-kappaB mediates mitogen-activated protein kinase pathway-dependent iNOS expression in human melanoma. J Invest Dermatol. 2009;129:148–54.
pubmed: 18668140
doi: 10.1038/jid.2008.205
Diaz-Ramón JL, Gardeazabal J, Izu RM, Garrote E, Rasero J, Apraiz A, et al. Melanoma clinical decision support system: an artificial intelligence-based tool to diagnose and predict disease outcome in early-stage melanoma patients. Cancers (Basel). 2023;15
Zou Y, Uddin MM, Padmanabhan S, Zhu Y, Bu P, Vancura A, et al. The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells. J Biol Chem. 2018;293:15483–96.
pubmed: 30135206
pmcid: 6177577
doi: 10.1074/jbc.RA118.004084
Ahlqvist K, Saamarthy K, Syed Khaja AS, Bjartell A, Massoumi R. Expression of id proteins is regulated by the Bcl-3 proto-oncogene in prostate cancer. Oncogene. 2013;32:1601–8.
pubmed: 22580608
doi: 10.1038/onc.2012.175
de Souza Braga M, da Silva Paiva KB, Foguer K, Barbosa Chaves KC, de Sá Lima L, Scavone C, et al. Involvement of the NF-кB/p50/Bcl-3 complex in response to antiangiogenic therapy in a mouse model of metastatic renal cell carcinoma. Biomed Pharmacother. 2014;68:873–9.
pubmed: 25113400
doi: 10.1016/j.biopha.2014.07.008
Dai J, Lu Y, Wang J, Yang L, Han Y, Wang Y, et al. A four-gene signature predicts survival in clear-cell renal-cell carcinoma. Oncotarget. 2016;7:82712–26.
pubmed: 27779101
pmcid: 5347726
doi: 10.18632/oncotarget.12631
Saamarthy K, Björner S, Johansson M, Landberg G, Massoumi R, Jirström K, et al. Early diagnostic value of Bcl-3 localization in colorectal cancer. BMC Cancer. 2015;15:341.
pubmed: 25929479
pmcid: 4434567
doi: 10.1186/s12885-015-1342-6
Tao Y, Liu Z, Hou Y, Wang S, Liu S, Jiang Y, et al. Alternative NF-κB signaling promotes colorectal tumorigenesis through transcriptionally upregulating Bcl-3. Oncogene. 2018;37:5887–900.
pubmed: 29973688
doi: 10.1038/s41388-018-0363-4
Zhang S, Yin C. BCL-3 and β-catenin signaling and tumor staging in colorectal cancer. Cell Mol Biol (Noisy-le-grand). 2020;66:87–91.
pubmed: 33040819
doi: 10.14715/cmb/2020.66.5.16
Fan S, Wu N, Chang S, Chen L, Sun X. The immune regulation of BCL3 in glioblastoma with mutated IDH1. Aging (Albany NY). 2022;14:3856–73.
pubmed: 35488886
pmcid: 9134951
doi: 10.18632/aging.204048
Wu L, Bernal GM, Cahill KE, Pytel P, Fitzpatrick CA, Mashek H, et al. BCL3 expression promotes resistance to alkylating chemotherapy in gliomas. Sci Transl Med. 2018;10
Puccio I, Khan S, Butt A, Graham D, Sehgal V, Patel D, et al. Immunohistochemical assessment of Survivin and Bcl3 expression as potential biomarkers for NF-κB activation in the Barrett metaplasia-dysplasia-adenocarcinoma sequence. Int J Exp Pathol. 2018;99:10–4.
pubmed: 29473241
pmcid: 5917386
doi: 10.1111/iep.12260
Soares-Lima SC, Gonzaga IM, Camuzi D, Nicolau-Neto P, Vieira da Silva R, Guaraldi S, et al. IL6 and BCL3 expression are potential biomarkers in esophageal squamous cell carcinoma. Front Oncol. 2021;11:722417.
pubmed: 34422669
pmcid: 8371528
doi: 10.3389/fonc.2021.722417
Dimitrakopoulos FI, Antonacopoulou AG, Kottorou A, Marousi S, Koukourikou I, Kalofonou M, et al. Variant of BCL3 gene is strongly associated with five-year survival of non-small-cell lung cancer patients. Lung Cancer. 2015;89:311–9.
pubmed: 26122346
doi: 10.1016/j.lungcan.2015.06.006
Dimitrakopoulos FD, Antonacopoulou AG, Kottorou AE, Panagopoulos N, Kalofonou F, Sampsonas F, et al. Expression of intracellular components of the NF-κB alternative pathway (NF-κB2, RelB, NIK and Bcl3) is associated with clinical outcome of NSCLC patients. Sci Rep. 2019;9:14299.
pubmed: 31586084
pmcid: 6778110
doi: 10.1038/s41598-019-50528-y
Xiao Z, Zhao H. Ferroptosis-related APOE, BCL3 and ALOX5AP gene polymorphisms are associated with the risk of thyroid Cancer. Pharmgenomics Pers Med. 2022;15:157–65.
pubmed: 35241926
pmcid: 8887669
Westerheide SD, Mayo MW, Anest V, Hanson JL, Baldwin AS Jr. The putative oncoprotein Bcl-3 induces cyclin D1 to stimulate G(1) transition. Mol Cell Biol. 2001;21:8428–36.
pubmed: 11713278
pmcid: 100006
doi: 10.1128/MCB.21.24.8428-8436.2001
Rocha S, Martin AM, Meek DW, Perkins ND. p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1. Mol Cell Biol. 2003;23:4713–27.
pubmed: 12808109
pmcid: 164841
doi: 10.1128/MCB.23.13.4713-4727.2003
Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fässler R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell. 2006;125:665–77.
pubmed: 16713561
doi: 10.1016/j.cell.2006.03.041
Bauer A, Villunger A, Labi V, Fischer SF, Strasser A, Wagner H, et al. The NF-kappaB regulator Bcl-3 and the BH3-only proteins Bim and Puma control the death of activated T cells. Proc Natl Acad Sci U S A. 2006;103:10979–84.
pubmed: 16832056
pmcid: 1544160
doi: 10.1073/pnas.0603625103
Park SG, Chung C, Kang H, Kim JY, Jung G. Up-regulation of cyclin D1 by HBx is mediated by NF-kappaB2/BCL3 complex through kappaB site of cyclin D1 promoter. J Biol Chem. 2006;281:31770–7.
pubmed: 16940298
doi: 10.1016/S0021-9258(19)84092-9
Mitsui T, Ishida M, Izawa M, Kagami Y, Arita J. Inhibition of Bcl3 gene expression mediates the anti-proliferative action of estrogen in pituitary lactotrophs in primary culture. Mol Cell Endocrinol. 2011;345:68–78.
pubmed: 21787835
doi: 10.1016/j.mce.2011.07.021
Mitchell TC, Thompson BS, Trent JO, Casella CR. A short domain within Bcl-3 is responsible for its lymphocyte survival activity. Ann N Y Acad Sci. 2002;975:132–47.
pubmed: 12538160
doi: 10.1111/j.1749-6632.2002.tb05947.x
Kashatus D, Cogswell P, Baldwin AS. Expression of the Bcl-3 proto-oncogene suppresses p53 activation. Genes Dev. 2006;20:225–35.
pubmed: 16384933
pmcid: 1356113
doi: 10.1101/gad.1352206
Bourteele S, Oesterle K, Weinzierl AO, Paxian S, Riemann M, Schmid RM, et al. Alteration of NF-kappaB activity leads to mitochondrial apoptosis after infection with pathological prion protein. Cell Microbiol. 2007;9:2202–17.
pubmed: 17573907
pmcid: 2048569
doi: 10.1111/j.1462-5822.2007.00950.x
Hanahan D. Hallmarks of Cancer: new dimensions. Cancer Discov. 2022;12:31–46.
pubmed: 35022204
doi: 10.1158/2159-8290.CD-21-1059
Massoumi R, Kuphal S, Hellerbrand C, Haas B, Wild P, Spruss T, et al. Down-regulation of CYLD expression by snail promotes tumor progression in malignant melanoma. J Exp Med. 2009;206:221–32.
pubmed: 19124656
pmcid: 2626666
doi: 10.1084/jem.20082044
Voce DJ, Bernal GM, Cahill KE, Wu L, Mansour N, Crawley CD, et al. CDK1 is up-regulated by temozolomide in an NF-κB dependent manner in glioblastoma. Sci Rep. 2021;11:5665.
pubmed: 33707466
pmcid: 7952566
doi: 10.1038/s41598-021-84912-4
García I, Cosío G, Lizárraga F, Martínez-Ruiz G, Meléndez-Zajgla J, Ceballos G, et al. Bcl-3 regulates UVB-induced apoptosis. Hum Cell. 2013;26:47–55.
pubmed: 23494744
doi: 10.1007/s13577-012-0056-1
Soukupová J, Bordoni C, Turnham DJ, Yang WW, Seaton G, Gruca A, et al. The discovery of a novel Antimetastatic Bcl3 inhibitor. Mol Cancer Ther. 2021;20:775–86.
pubmed: 33649105
doi: 10.1158/1535-7163.MCT-20-0283
Turnham DJ, Yang WW, Davies J, Varnava A, Ridley AJ, Conlan RS, et al. Bcl-3 promotes multi-modal tumour cell migration via NF-κB1 mediated regulation of Cdc42. Carcinogenesis. 2020;41:1432–43.
pubmed: 31957805
doi: 10.1093/carcin/bgaa005
Hu L, Bai Z, Ma X, Bai N, Zhang Z. The influence of Bcl-3 expression on cell migration and Chemosensitivity of gastric Cancer cells via regulating hypoxia-induced protective autophagy. J Gastric Cancer. 2020;20:95–105.
pubmed: 32269848
pmcid: 7105414
doi: 10.5230/jgc.2020.20.e9
Zamora R, Espinosa M, Ceballos-Cancino G, Segura B, Maldonado V, Melendez-Zajgla J. Depletion of the oncoprotein Bcl-3 induces centrosome amplification and aneuploidy in cancer cells. Mol Cancer. 2010;9:223.
pubmed: 20731879
pmcid: 2933622
doi: 10.1186/1476-4598-9-223
Gao C, Wang X, Chen L, Wang JH, Gao ZT, Wang H. Knockdown of Bcl-3 inhibits cell growth and induces DNA damage in HTLV-1-infected cells. Asian Pac J Cancer Prev. 2013;14:405–8.
pubmed: 23534762
doi: 10.7314/APJCP.2013.14.1.405
Parker C, Chambers AC, Flanagan DJ, Ho JWY, Collard TJ, Ngo G, et al. BCL-3 loss sensitises colorectal cancer cells to DNA damage by targeting homologous recombination. DNA Repair (Amst). 2022;115:103331.
pubmed: 35468497
pmcid: 10618080
doi: 10.1016/j.dnarep.2022.103331
Watanabe N, Wachi S, Fujita T. Identification and characterization of BCL-3-binding protein: implications for transcription and DNA repair or recombination. J Biol Chem. 2003;278:26102–10.
pubmed: 12730195
doi: 10.1074/jbc.M303518200
Wu D, Tian S, Zhu W. Modulating multidrug resistance to drug-based antitumor therapies through NF-κB signaling pathway: mechanisms and perspectives. Expert Opin Ther Targets. 2023;27:503–15.
pubmed: 37314372
doi: 10.1080/14728222.2023.2225767
Zhang X, Dong N, Hu X. Wnt/β-catenin signaling inhibitors. Curr Top Med Chem. 2023;23:880–96.
pubmed: 36872364
doi: 10.2174/1568026623666230303101810
Singh S, Gomez HJ, Thakkar S, Singh SP, Parihar AS. Overcoming acquired drug resistance to Cancer therapies through targeted STAT3 inhibition. Int J Mol Sci. 2023;24
Mansour NM, Bernal GM, Wu L, Crawley CD, Cahill KE, Voce DJ, et al. Decoy receptor DcR1 is induced in a p50/Bcl3-dependent manner and attenuates the efficacy of Temozolomide. Cancer Res. 2015;75:2039–48.
pubmed: 25808868
pmcid: 4433625
doi: 10.1158/0008-5472.CAN-14-2144
Ladoire S, Mignot G, Dabakuyo S, Arnould L, Apetoh L, Rébé C, et al. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol. 2011;224:389–400.
pubmed: 21437909
doi: 10.1002/path.2866
Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, et al. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A. 2008;105:14987–92.
pubmed: 18818309
pmcid: 2567480
doi: 10.1073/pnas.0806075105
Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Res. 2012;72:5209–18.
pubmed: 22915761
pmcid: 3476734
doi: 10.1158/0008-5472.CAN-12-1187
Gaire B, Padmanabhan S, Zou Y, Uddin MM, Reddy SU, Vancurova I. IFNγ induces Bcl3 expression by JAK1/STAT1/p65 signaling, resulting in increased IL-8 expression in ovarian cancer cells. FEBS Open Bio. 2023;13:1495–506.
pubmed: 37151134
pmcid: 10392061
doi: 10.1002/2211-5463.13624
Cilibrasi C, Papanastasopoulos P, Samuels M, Giamas G. Reconstituting immune surveillance in breast Cancer: molecular pathophysiology and current immunotherapy strategies. Int J Mol Sci. 2021;22(21):12015.
pubmed: 34769447
pmcid: 8584417
doi: 10.3390/ijms222112015
Padmanabhan S, Zou Y, Vancurova I. Immunoblotting analysis of intracellular PD-L1 levels in interferon-γ-treated ovarian Cancer cells stably transfected with Bcl3 shRNA. Methods Mol Biol. 2020;2108:211–20.
pubmed: 31939183
doi: 10.1007/978-1-0716-0247-8_18
Yang M, Zhang G, Wang Y, He M, Xu Q, Lu J, et al. Tumour-associated neutrophils orchestrate intratumoural IL-8-driven immune evasion through Jagged2 activation in ovarian cancer. Br J Cancer. 2020;123:1404–16.
pubmed: 32778818
pmcid: 7591527
doi: 10.1038/s41416-020-1026-0
Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221:107753.
pubmed: 33259885
doi: 10.1016/j.pharmthera.2020.107753
Hu Y, Zhang H, Xie N, Liu D, Jiang Y, Liu Z, et al. Bcl-3 promotes TNF-induced hepatocyte apoptosis by regulating the deubiquitination of RIP1. Cell Death Differ. 2022;29:1176–86.
pubmed: 34853447
doi: 10.1038/s41418-021-00908-7
Smalley M, Piggott L, Clarkson R. Breast cancer stem cells: obstacles to therapy. Cancer Lett. 2013;338:57–62.
pubmed: 22554712
doi: 10.1016/j.canlet.2012.04.023
Nairuz T, Mahmud Z, Manik RK, Kabir Y. Cancer stem cells: an insight into the development of metastatic tumors and therapy resistance. Stem Cell Rev Rep. 2023;19:1577–95.
pubmed: 37129728
doi: 10.1007/s12015-023-10529-x
Carr D, Zein A, Coulombe J, Jiang T, Cabrita MA, Ward G, et al. Multiple roles for Bcl-3 in mammary gland branching, stromal collagen invasion, involution and tumor pathology. Breast Cancer Res. 2022;24:40.
pubmed: 35681213
pmcid: 9185916
doi: 10.1186/s13058-022-01536-w
Kang S, Yun J, Kim DY, Jung SY, Kim YJ, Park JH, et al. Adequate concentration of B cell leukemia/lymphoma 3 (Bcl3) is required for pluripotency and self-renewal of mouse embryonic stem cells via downregulation of Nanog transcription. BMB Rep. 2018;51:92–7.
pubmed: 29335071
pmcid: 5836563
doi: 10.5483/BMBRep.2018.51.2.219
Ai J, Wörmann SM, Görgülü K, Vallespinos M, Zagorac S, Alcala S, et al. Bcl3 couples Cancer stem cell enrichment with pancreatic Cancer molecular subtypes. Gastroenterology. 2021;161:318–332.e319.
pubmed: 33819482
doi: 10.1053/j.gastro.2021.03.051
Tang W, Wang H, Ha HL, Tassi I, Bhardwaj R, Claudio E, et al. The B-cell tumor promoter Bcl-3 suppresses inflammation-associated colon tumorigenesis in epithelial cells. Oncogene. 2016;35:6203–11.
pubmed: 27132515
pmcid: 5093091
doi: 10.1038/onc.2016.152
Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, et al. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev. 1997;11:3482–96.
pubmed: 9407039
pmcid: 316809
doi: 10.1101/gad.11.24.3482
Anderson RL, Balasas T, Callaghan J, Coombes RC, Evans J, Hall JA, et al. A framework for the development of effective anti-metastatic agents. Nat Rev Clin Oncol. 2019;16:185–204.
pubmed: 30514977
doi: 10.1038/s41571-018-0134-8
Han Y, Shin SH, Lim CG, Heo YH, Choi IY, Kim HH. Synthetic RNA therapeutics in Cancer. J Pharmacol Exp Ther. 2023;386:212–23.
pubmed: 37188531
doi: 10.1124/jpet.123.001587
Guan Y, Yao H, Zheng Z, Qiu G, Sun K. MiR-125b targets BCL3 and suppresses ovarian cancer proliferation. Int J Cancer. 2011;128:2274–83.
pubmed: 20658525
doi: 10.1002/ijc.25575
Wang J, Chen T, Wang L, Yao B, Sun L, Chen S, et al. MicroRNA-627-5p inhibits the proliferation of hepatocellular carcinoma cells by targeting BCL3 transcription coactivator. Clin Exp Pharmacol Physiol. 2020;47:485–94.
pubmed: 31793036
doi: 10.1111/1440-1681.13218
Wang J, Liu R, Wang Y, Mo H, Niu Y, Xu Q, et al. Repression of the miR-627-5p by histone deacetylase 3 contributes to hypoxia-induced hepatocellular carcinoma progression. J Cancer. 2021;12:5320–30.
pubmed: 34335948
pmcid: 8317525
doi: 10.7150/jca.58697
Sun D, Zhao Y, Wang W, Guan C, Hu Z, Liu L, et al. PCAT1 induced by transcription factor YY1 promotes cholangiocarcinoma proliferation, migration and invasion by sponging miR-216a-3p to up-regulate oncogene BCL3. Biol Chem. 2021;402:207–19.
pubmed: 33544468
doi: 10.1515/hsz-2020-0276
Ge P, Chen X, Liu J, Jing R, Zhang X, Li H. Hsa_circ_0088036 promotes nonsmall cell lung cancer progression by regulating miR-1343-3p/Bcl-3 axis through TGFβ/Smad3/EMT signaling. Mol Carcinog. 2023;62:1073–85.
pubmed: 37132942
doi: 10.1002/mc.23547
Jamaluddin M, Choudhary S, Wang S, Casola A, Huda R, Garofalo RP, et al. Respiratory syncytial virus-inducible BCL-3 expression antagonizes the STAT/IRF and NF-kappaB signaling pathways by inducing histone deacetylase 1 recruitment to the interleukin-8 promoter. J Virol. 2005;79:15302–13.
pubmed: 16306601
pmcid: 1316019
doi: 10.1128/JVI.79.24.15302-15313.2005
Zhao Y, Ramakrishnan A, Kim KE, Rabson AB. Regulation of Bcl-3 through interaction with the Lck tyrosine kinase. Biochem Biophys Res Commun. 2005;335:865–73.
pubmed: 16099425
doi: 10.1016/j.bbrc.2005.07.162
Bundy DL, McKeithan TW. Diverse effects of BCL3 phosphorylation on its modulation of NF-kappaB p52 homodimer binding to DNA. J Biol Chem. 1997;272:33132–9.
pubmed: 9407099
doi: 10.1074/jbc.272.52.33132
Massoumi R. CYLD: a deubiquitination enzyme with multiple roles in cancer. Future Oncol. 2011;7:285–97.
pubmed: 21345146
doi: 10.2217/fon.10.187